Cargando…

Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis

Ankylosing spondylitis is a chronic immune-mediated inflammatory arthritis. Interleukin-17A (IL-17A) inhibitors is recognized as a novel therapeutic target for ankylosing spondylitis. However, there is still a lack of high-quality research evidence regarding the issues. Therefore, we performed a pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Mingguang, Fang, Xiao, Guo, Jianjun, Yin, Weibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750646/
https://www.ncbi.nlm.nih.gov/pubmed/36626473
http://dx.doi.org/10.1097/MD.0000000000032224
_version_ 1784850302188388352
author Yan, Mingguang
Fang, Xiao
Guo, Jianjun
Yin, Weibing
author_facet Yan, Mingguang
Fang, Xiao
Guo, Jianjun
Yin, Weibing
author_sort Yan, Mingguang
collection PubMed
description Ankylosing spondylitis is a chronic immune-mediated inflammatory arthritis. Interleukin-17A (IL-17A) inhibitors is recognized as a novel therapeutic target for ankylosing spondylitis. However, there is still a lack of high-quality research evidence regarding the issues. Therefore, we performed a protocol for systematic review and meta-analysis to evaluate the efficacy and safety of IL-17A inhibitors in patients with ankylosing spondylitis. METHODS: This protocol will be conducted under the preferred reporting items for systematic reviews and meta-analyses protocols (PRISMA-P) guidelines. Furthermore, the study has been registered on PROSPERO (CRD42022375885). The following electronic databases will be searched regardless of language and publication status: Pubmed, MEDLINE, EMBASE, China Biomedical Database, China National Knowledge Infrastructure, VIP Database, and Wanfang Database. Cochrane “bias risk” tool is used to assess the bias risk of the quality of the included literature. Data synthesis and statistical analysis will be performed using the RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) software. RESULTS: A synthesis of current evidence of IL-17A inhibitors for ankylosing spondylitis will be shown in this protocol. CONCLUSION: This review can provide convincing evidence to help clinicians make decisions when dealing with ankylosing spondylitis.
format Online
Article
Text
id pubmed-9750646
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97506462022-12-28 Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis Yan, Mingguang Fang, Xiao Guo, Jianjun Yin, Weibing Medicine (Baltimore) 7100 Ankylosing spondylitis is a chronic immune-mediated inflammatory arthritis. Interleukin-17A (IL-17A) inhibitors is recognized as a novel therapeutic target for ankylosing spondylitis. However, there is still a lack of high-quality research evidence regarding the issues. Therefore, we performed a protocol for systematic review and meta-analysis to evaluate the efficacy and safety of IL-17A inhibitors in patients with ankylosing spondylitis. METHODS: This protocol will be conducted under the preferred reporting items for systematic reviews and meta-analyses protocols (PRISMA-P) guidelines. Furthermore, the study has been registered on PROSPERO (CRD42022375885). The following electronic databases will be searched regardless of language and publication status: Pubmed, MEDLINE, EMBASE, China Biomedical Database, China National Knowledge Infrastructure, VIP Database, and Wanfang Database. Cochrane “bias risk” tool is used to assess the bias risk of the quality of the included literature. Data synthesis and statistical analysis will be performed using the RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) software. RESULTS: A synthesis of current evidence of IL-17A inhibitors for ankylosing spondylitis will be shown in this protocol. CONCLUSION: This review can provide convincing evidence to help clinicians make decisions when dealing with ankylosing spondylitis. Lippincott Williams & Wilkins 2022-12-09 /pmc/articles/PMC9750646/ /pubmed/36626473 http://dx.doi.org/10.1097/MD.0000000000032224 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 7100
Yan, Mingguang
Fang, Xiao
Guo, Jianjun
Yin, Weibing
Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis
title Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis
title_full Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis
title_fullStr Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis
title_full_unstemmed Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis
title_short Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis
title_sort effectiveness of interleukin-17a inhibitors in patients with ankylosing spondylitis: a protocol for systematic review and meta-analysis
topic 7100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750646/
https://www.ncbi.nlm.nih.gov/pubmed/36626473
http://dx.doi.org/10.1097/MD.0000000000032224
work_keys_str_mv AT yanmingguang effectivenessofinterleukin17ainhibitorsinpatientswithankylosingspondylitisaprotocolforsystematicreviewandmetaanalysis
AT fangxiao effectivenessofinterleukin17ainhibitorsinpatientswithankylosingspondylitisaprotocolforsystematicreviewandmetaanalysis
AT guojianjun effectivenessofinterleukin17ainhibitorsinpatientswithankylosingspondylitisaprotocolforsystematicreviewandmetaanalysis
AT yinweibing effectivenessofinterleukin17ainhibitorsinpatientswithankylosingspondylitisaprotocolforsystematicreviewandmetaanalysis